Related Experiment Video
Updated: Jun 12, 2026

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
Published on: February 5, 2019
Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study
Jennifer L Miller1, Roy Tamura2, Merlin G Butler3
1Departmentof Pediatrics College of Medicine, University of Florida, Gainesville, Florida.
Insights
Intranasal oxytocin (IN-OT) shows promise as a safe treatment for Prader-Willi syndrome (PWS). This study suggests IN-OT may reduce appetite and improve social behaviors, anxiety, and repetitive actions in individuals with PWS.
Area of Science:
- Neuroendocrinology
- Genetics
- Pediatric Medicine
Background:
- Prader-Willi syndrome (PWS) is a complex genetic disorder characterized by hypothalamic dysfunction, hyperphagia, and behavioral issues.
- Individuals with PWS exhibit a deficit in oxytocin-producing neurons, impacting feeding, social interaction, and emotional regulation.
- Oxytocin's role in regulating key behaviors affected by PWS necessitates investigation into its therapeutic potential.
Purpose of the Study:
- To evaluate the safety and efficacy of intranasal oxytocin (IN-OT) in children with Prader-Willi syndrome.
- To assess the impact of IN-OT on hyperphagia, social behaviors, anxiety, and repetitive behaviors in PWS patients.
- To determine the short-term effects of IN-OT compared to placebo in a pediatric PWS population.
Main Methods:
- A double-blind, placebo-controlled, crossover study involving 24 children with PWS.
- Participants received either 5 days of IN-OT or placebo, followed by a 4-week washout, then the alternate treatment.
- Evaluations included standardized behavioral questionnaires, Clinical Global Impression scales, safety labs, and dietary assessments.
Main Results:
- Improvements in various behavioral and clinical factors from Day 3 to Day 6 favored oxytocin over placebo.
- No statistically significant differences were observed between groups at Day 6 for any single factor.
- Observed drug effects diminished by Day 14, with no significant safety concerns or changes in weight or diet parameters.
Conclusions:
- Low-dose intranasal oxytocin appears safe for individuals with Prader-Willi syndrome.
- IN-OT may offer potential benefits in reducing appetite drive and improving socialization, anxiety, and repetitive behaviors.
- Further long-term studies with larger cohorts are required to confirm these preliminary findings and establish efficacy.
Abstract:
Prader-Willi syndrome (PWS) is a rare, complex multisystem genetic disorder which includes hypothalamic dysfunction, hyperphagia, cognitive and behavioral problems, increased anxiety, and compulsive behaviors. Individuals with PWS have a deficit of oxytocin producing neurons in the paraventricular nucleus of the hypothalamus. Oxytocin plays a role in regulation of feeding behaviors, social interactions, and emotional reactivity, which are all issues that significantly affect the quality of life for individuals with this syndrome. We performed a double-blind, placebo-controlled, crossover study in 24 children with PWS at three academic institutions using 5 days of intranasal oxytocin (IN-OT) or 5 days of intranasal placebo spray, followed by a 4 week washout period, and then patients returned for 5 days of treatment with the alternate source. Questionnaires, including the Aberrant Behavior Checklist, Social Responsiveness Scale, Repetitive Behavior Scale - Revised, and the Hyperphagia Questionnaire, as well as Clinical Global Impression scales were administered. Blood testing for sodium, potassium, and glucose levels on days 2, 4, and 6, and a 24 hr diet recall. All scales factor improvement from Day 3 to Day 6 favored oxytocin over placebo. No single factor showed a statistically significant difference (P < 0.05) between groups at Day 6. The drug effect appeared to be diminished at Day 14. There was no evidence of a difference between oxytocin and placebo in safety lab parameters, 60 min post dose vital signs, weight, or diet parameters. The results from this study suggest that low dose intranasal oxytocin is safe for individuals with PWS and may result in reduction in appetite drive, and improvements in socialization, anxiety, and repetitive behaviors. Further, long-term studies with a larger population of participants are necessary to confirm these findings. The results of this study are encouraging that oxytocin may be a safe and effective treatment for many of the issues that negatively impact individuals with PWS.
More Related Videos
07:20Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
Published on: August 9, 2024
11:17Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
Related Concept Videos
Blind Procedures
Blinding
Drug Dosing: Infants and Children